Who owns MLYS? 13F holders and whale ownership
MLYS is tracked across public portfolios in Whale Analyzer. This page answers who owns MLYS, which top funds are buying MLYS, aggregate disclosed value, and recent position changes based on public data. Peter Kolchinsky is the largest reported holder at $208M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (2 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $3.82. Top tracked holders include Peter Kolchinsky and Samuel Isaly.
Continue to the live MLYS dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Peter Kolchinsky 13F portfolio RA Capital Management holdings | $208.4M | 7.7M | Increased |
| Samuel Isaly 13F portfolio OrbiMed Advisors holdings | $55.6M | 2.1M | Increased |
Ownership concentration
Reported ownership of MLYS is highly concentrated across tracked institutions.
- Single largest holder: 78.9% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 2 increased. Net positioning is net buying.
- Peter Kolchinsky — RA Capital Management ($208.4M) (▲ 5.0% qoq shares)
- Samuel Isaly — OrbiMed Advisors ($55.6M) (▲ 109.4% qoq shares) · avg cost $3.82
Whale cost basis vs current price
The aggregate tracked cost basis is $3.82 versus a current price of $26.68, so MLYS trades above its cost basis (+597.9%). Average unrealized P&L across tracked holders: 644%.
Sector positioning — Health Care
MLYS sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live MLYS dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- ASND whale holders — ASCENDIS PHARMA A/S - ADR
- PCVX whale holders — VAXCYTE INC
- RYTM whale holders — RHYTHM PHARMACEUTICALS INC
- TYRA whale holders — TYRA BIOSCIENCES INC
- SION whale holders — SIONNA THERAPEUTICS INC
- EWTX whale holders — EDGEWISE THERAPEUTICS INC
- NAMSW whale holders — NEWAMSTERDAM PHARMA CO NV
- NUVL whale holders — NUVALENT INC-A
Learn more in Whale Analyzer Academy
Deepen your read on MLYS with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns MLYS stock?
Whale Analyzer tracks 2 public institutional holders of MLYS with a combined reported value of $264.0M. See the holder table above for the largest tracked positions.
Which top funds are buying MLYS?
Tracked institutions were net buying last quarter — 2 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is MLYS ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is MLYS above or below the whale cost basis?
The aggregate tracked cost basis is $3.82 versus a current price of $26.68 (+597.9%).
What does 13F ownership mean for MLYS?
Use the interactive MLYS dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.